ArticleCell death & disease2025
Integrated genetic and epigenetic analysis identifies that rs939408 affects non-smoking lung adenocarcinoma risk by modulating the DNA methylation of LRRC2.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TRIM26-mediated NKRF degradation drives Osimertinib resistance through SNRPD2-dependent stress granule formation in lung adenocarcinoma.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the relationship between methylation quantitative trait loci (meQTL) and lung adenocarcinoma (LUAD) susceptibility. Candidate SNPs linked to differentially methylated CpG sites in LUAD were identified through meQTL datasets. Genome-wide association study (GWAS) data were analyzed to assess the correlation between selected meQTLs and LUAD risk. The effects of target genes on malignant LUAD phenotypes were examined through both in vitro and in vivo experiments. Additionally, machine learning and radiomics models were employed to evaluate the association of target genes on LUAD progression. The variant A allele of rs939408 was associated with decreased methylation levels of cg09596674 in LRRC2 (β < 0, P < 0.001). While cg09596674 was highly methylated, LRRC2 showed lower expression in LUAD tumor tissues. Consistently, a negative correlation was observed between methylation of cg09596674 and LRRC2 expression (r = -0.32, P < 0.001), indicating that lower methylation of cg09596674 modulated by rs939408 may reduce non-smoking LUAD risk (OR = 0.89, P = 0.019). Increased LRRC2 expression inhibited LUAD cell line malignancy and suppressed tumor growth in mice. Furthermore, lower LRRC2 expression was linked to metastasis (P = 0.02) and higher levels of two poorer survival-related imaging features (P = 0.03). The meQTL rs939408 may modulate DNA methylation of LRRC2, thereby influencing its expression and potentially affecting non-smoking LUAD risk. These findings offer valuable insights into the role of meQTLs in LUAD carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.